Treatment management of favourable risk and very favourable risk patients

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Key insights from head and neck research at ASCO 2025

ASCO 2025: Developments in the treatment of soft tissue sarcoma

Transforming cancer care in India: The Access Cancer Care Initiative

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia